Simulations Plus (NASDAQ:SLP) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued on Friday, ValuEngine reports.

Several other research firms have also recently issued reports on SLP. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Zacks Investment Research cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th.

NASDAQ:SLP opened at $32.14 on Friday. Simulations Plus has a 12-month low of $16.79 and a 12-month high of $32.85. The stock’s 50-day simple moving average is $27.19. The stock has a market capitalization of $547.68 million, a PE ratio of 64.28 and a beta of -0.38.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. The firm had revenue of $9.94 million during the quarter, compared to analysts’ expectations of $9.85 million. Equities analysts forecast that Simulations Plus will post 0.44 EPS for the current fiscal year.

In related news, Chairman Walter S. Woltosz sold 18,500 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $22.11, for a total transaction of $409,035.00. Following the completion of the transaction, the chairman now directly owns 5,196,039 shares of the company’s stock, valued at $114,884,422.29. The sale was disclosed in a filing with the SEC, which is available through this link. 31.57% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in shares of Simulations Plus by 48.5% in the fourth quarter. Rhumbline Advisers now owns 15,309 shares of the technology company’s stock valued at $305,000 after purchasing an additional 5,000 shares during the last quarter. Royce & Associates LP raised its holdings in shares of Simulations Plus by 6,319.2% in the fourth quarter. Royce & Associates LP now owns 50,712 shares of the technology company’s stock valued at $1,009,000 after purchasing an additional 49,922 shares during the last quarter. Advisor Group Inc. increased its holdings in Simulations Plus by 156.9% during the fourth quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock worth $42,000 after buying an additional 1,290 shares during the last quarter. Bessemer Group Inc. increased its holdings in Simulations Plus by 8.6% during the fourth quarter. Bessemer Group Inc. now owns 31,700 shares of the technology company’s stock worth $631,000 after buying an additional 2,500 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Simulations Plus by 4.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 571,865 shares of the technology company’s stock worth $11,380,000 after buying an additional 25,871 shares during the last quarter. 41.28% of the stock is owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Recommended Story: How does new data get added to a blockchain?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.